5 Key Takeaways

• 1

  The FDA has approved Odactra for pediatric patients aged 5 to 11 years with house dust mite-induced allergic rhinitis.

• 2

  Odactra was previously approved for patients aged 12 to 65 years and is developed by ALK.

• 3

  The approval is based on data from the MT-12 trial, a phase III study involving 1,460 pediatric patients.

• 4

  House dust mites are a leading cause of respiratory allergic disease, affecting over 10 million children globally.

• 5

  Odactra is marketed internationally under various brand names and has received pediatric approval in Europe and Japan.